...
首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition
【24h】

Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition

机译:人UDP-葡萄糖醛酸转移酶(UGT)2B10:可替宁作为选择性探针底物的验证,UGT酶选择性抑制剂和抗抑郁药和抗精神病药的抑制作用以及酶抑制作用的结构决定因素

获取原文
获取原文并翻译 | 示例
           

摘要

Although there is evidence for an important role of UGT2B10 in the N-glucuronidation of drugs and other xenobiotics, the inhibitor selectivity of this enzyme is poorly understood. This study sought primarily to characterize the inhibition selectivity of UGT2B10 by UDP-glucuronosyltransferase (UGT) enzyme-selective inhibitors used for reaction phenotyping, and 34 antidepressant and antipsychotic drugs that contain an amine functional group. Initial studies demonstrated that cotinine is a highly selective substrate of human liver microsomal UGT2B10. The kinetics of cotinine N-glucuronidation by recombinant UGT and human liver microsomes (6 bovine serum albumin) were consistent with the involvement of a single enzyme. Of the UGT enzyme-selective inhibitors employed for reaction phenotyping, only the UGT2B4/7 inhibitor fluconazole reduced recombinant UGT2B10 activity to an appreciable extent. The majority of antidepressant and antipsychotic drugs screened for effects on UGT2B10 inhibited enzyme activity with IC50 values <100 mu M. The most potent inhibition was observed with the tricyclic antidepressants amitriptyline and doxepin and the tetracyclic antidepressant mianserin, and the structurally related compounds desloratadine and loratadine. Molecular modeling using a ligand-based approach indicated that hydrophobic and charge interactions are involved in inhibitor binding, whereas spatial features influence the potency of UGT2B10 inhibition. Respective mean K-i,K-u (+/- S. D.) values for amitriptyline, doxepin, and mianserin inhibition of human liver microsomal UGT2B10 were 0.61 +/- 0.05, 0.95 +/- 0.18, and 0.43 +/- 0.01 mM. In vitro-in vivo extrapolation indicates that these drugs may perpetrate inhibitory drug-drug interactions when coadministered with compounds that are cleared predominantly by UGT2B10.
机译:尽管有证据表明UGT2B10在药物和其他异源生物的N-葡萄糖醛酸苷化中具有重要作用,但对该酶的抑制剂选择性知之甚少。这项研究的主要目的是表征用于反应表型的UDP-葡萄糖醛糖基转移酶(UGT)酶选择性抑制剂对UGT2B10的抑制选择性,以及34种含有胺官能团的抗抑郁药和抗精神病药。初步研究表明,可替宁是人肝微粒体UGT2B10的高度选择性底物。重组UGT和人肝微粒体(6个牛血清白蛋白)可替宁N-葡萄糖醛酸化的动力学与单一酶的参与是一致的。在用于反应表型的UGT酶选择性抑制剂中,只有UGT2B4 / 7抑制剂氟康唑可将重组UGT2B10活性显着降低。多数抗抑郁药和抗精神病药筛选了对UGT2B10抑制酶活性的作用,IC50值<100μM。最有效的抑制作用是三环抗抑郁药阿米替林和多塞平以及四环抗抑郁药曼塞林,以及与结构相关的化合物去氯雷他定和氯雷他定。使用基于配体的方法进行分子建模表明,疏水性和电荷相互作用与抑制剂结合有关,而空间特征影响UGT2B10抑制的效力。阿米替林,多塞平和米安色林抑制人肝微粒体UGT2B10的各自平均K-i,K-u(+/- S.D.)值为0.61 +/- 0.05、0.95 +/- 0.18和0.43 +/- 0.01 mM。体外-体内外推法表明,当这些药物与主要由UGT2B10清除的化合物共同给药时,它们可能会产生抑制性药物-药物相互作用。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号